TY - JOUR
T1 - Assessing rates and predictors of tachyphylaxis during the prevention of recurrent episodes of depression with venlafaxine ER for two years (PREVENT) study
AU - Rothschild, Anthony J.
AU - Dunlop, Boadie W.
AU - Dunner, David L.
AU - Friedman, Edward S.
AU - Gelenberg, Alan
AU - Holland, Peter
AU - Kocsis, James H.
AU - Kornstein, Susan G.
AU - Shelton, Richard
AU - Trivedi, Madhukar H.
AU - Zajecka, John M.
AU - Goldstein, Corey
AU - Thase, Michael E.
AU - Pedersen, Ron
AU - Keller, Martin B.
PY - 2009
Y1 - 2009
N2 - Background: Antidepressant tachyphylaxis describes the return of apathetic depressive symptoms, such as fatigue and decreased motivation, despite continued use of a previously effective treatment. Methods: Data were collected from a multiphase, double-blind, placebo-controlled study that assessed the efficacy of venlafaxine extended release (ER) during 2 sequential 1-year maintenance phases (A and B) in patients with recurrent major depressive disorder (MDD). The primary outcome was the cumulative probability of tachyphylaxis in patients receiving venlafaxine ER, fluoxetine, or placebo. Tachyphylaxis was defined as Rothschild Scale for Antidepressant Tachyphylaxis (RSAT) score ≥ 7 in patients with prior satisfactory therapeutic response. A Kaplan-Meier estimate of the cumulative probability of not experiencing tachyphylaxis, and a 2-sided Fisher exact test was used to assess the relationship between tachyphylaxis and recurrence. Results: The maintenance phase A population was comprised of 337 patients (venlafaxine ER [n = 129], fluoxetine [n = 79], placebo [n = 129]), whereas 128 patients (venlafaxine ER [n = 43], fluoxetine [n = 45], placebo [n = 40]) were tre a ted during maintenance phase B. No difference in the probability of experiencing tachyphylaxis were observed between the active treatment groups during either maintenance phase; however, a significant difference between venlafaxine ER and placebo was observed at the completion of maintenance phase A. A significant relationship between tachyphylaxis and recurrence was observed. Limitations: Despite demonstrating psychometric validity and reliability, the current definition of tachyphylaxis has not been widely studied. Conclusions: Although no significant differences were observed in the probability of tachyphylaxis among patients receiving active treatment, the relationship between tachyphylaxis and recurrence suggests that tachyphylaxis may be a prodrome of recurrence.
AB - Background: Antidepressant tachyphylaxis describes the return of apathetic depressive symptoms, such as fatigue and decreased motivation, despite continued use of a previously effective treatment. Methods: Data were collected from a multiphase, double-blind, placebo-controlled study that assessed the efficacy of venlafaxine extended release (ER) during 2 sequential 1-year maintenance phases (A and B) in patients with recurrent major depressive disorder (MDD). The primary outcome was the cumulative probability of tachyphylaxis in patients receiving venlafaxine ER, fluoxetine, or placebo. Tachyphylaxis was defined as Rothschild Scale for Antidepressant Tachyphylaxis (RSAT) score ≥ 7 in patients with prior satisfactory therapeutic response. A Kaplan-Meier estimate of the cumulative probability of not experiencing tachyphylaxis, and a 2-sided Fisher exact test was used to assess the relationship between tachyphylaxis and recurrence. Results: The maintenance phase A population was comprised of 337 patients (venlafaxine ER [n = 129], fluoxetine [n = 79], placebo [n = 129]), whereas 128 patients (venlafaxine ER [n = 43], fluoxetine [n = 45], placebo [n = 40]) were tre a ted during maintenance phase B. No difference in the probability of experiencing tachyphylaxis were observed between the active treatment groups during either maintenance phase; however, a significant difference between venlafaxine ER and placebo was observed at the completion of maintenance phase A. A significant relationship between tachyphylaxis and recurrence was observed. Limitations: Despite demonstrating psychometric validity and reliability, the current definition of tachyphylaxis has not been widely studied. Conclusions: Although no significant differences were observed in the probability of tachyphylaxis among patients receiving active treatment, the relationship between tachyphylaxis and recurrence suggests that tachyphylaxis may be a prodrome of recurrence.
KW - Loss of antidepressant response
KW - Major depressive disorder
KW - Psychopharmacology
KW - Rothschild scale for antidepressant
KW - Serotonin norepinephrine reuptake inhibitor
UR - http://www.scopus.com/inward/record.url?scp=77952963486&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77952963486&partnerID=8YFLogxK
M3 - Article
C2 - 19752838
AN - SCOPUS:77952963486
SN - 0048-5764
VL - 42
SP - 5
EP - 20
JO - Psychopharmacology Bulletin
JF - Psychopharmacology Bulletin
IS - 3
ER -